Financial incentives to promote extended smoking abstinence in opioid-maintained patients: A randomized trial

Addiction

Volumn 111, Issue 5, 2016, Pages 903-912

  Sigmon, Stacey C ^a,b   Miller, Mollie E ^a,b   Meyer, Andrew C ^a,b   Saulsgiver, Kathryn ^d   Badger, Gary J ^c   Heil, Sarah H ^a,b   Higgins, Stephen T ^a,b  

^a Vermont Center on Behavior and Health   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Behavioral; Buprenorphine; Contingency management; Incentive; Methadone; Opioid dependence; Smoking abstinence

Indexed keywords

AMFEBUTAMONE; CARBON MONOXIDE; COTININE; DOPAMINE UPTAKE INHIBITOR; NARCOTIC ANALGESIC AGENT;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; BREATH ANALYSIS; CONTROLLED STUDY; ECONOMICS; FEMALE; HUMAN; MALE; MIDDLE AGED; MOTIVATION; OPIOID-RELATED DISORDERS; PREVENTION AND CONTROL; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SMOKING; SMOKING CESSATION; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; ANALGESICS, OPIOID; BREATH TESTS; BUPROPION; CARBON MONOXIDE; COTININE; DOPAMINE UPTAKE INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTIVATION; OPIOID-RELATED DISORDERS; SELF REPORT; SMOKING; SMOKING CESSATION; YOUNG ADULT;

EID: 84958064024     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.13264     Document Type: Article

References (76)

1. Johnson R. E., Chutaupe M. A., Strain E. C., Walsh S. L., Stitzer M. L., Bigelow G. E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000; 343: 1290-7.
2. Mattick R. P., Breen C., Kimber J., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014; 2: CD002207.
3. Stotts A. L., Dodrill D. C., Kosten T. R. Opioid dependence treatment: options in pharmacotherapy. Exp Opin Pharmacother 2009; 10: 1727--40.
4. Stitzer M. L., Sigmon S. C. Other substance use disorders: prevalence, consequences, detection and management. In: Strain E. C., Stitzer M. L., editors. The Treatment of Opioid Dependence. Baltimore, MD: Johns Hopkins University Press; 2006, pp. 365-97.
5. Chait L. D., Griffiths R. R. Effects of methadone on human cigarette smoking and subjective ratings. J Pharmacol Exp Ther 1984; 229: 636-40.
6. Mello N. K., Mendelson J. H., Sellers M. L., Kuehnle J. C. Effects of heroin self-administration on cigarette smoking. Psychopharmacology (Berl) 1980; 67: 45-52.
7. Mello N. K., Lukas S. E., Mendelson J. H. Buprenorphine effects on cigarette smoking. Psychopharmacology (Berl) 1985; 86: 417-25.
8. Mutschler N. H., Stephen B. J., Teoh S. K., Mendelson J. H., Mello N. K. An inpatient study of the effects of buprenorphine on cigarette smoking in men concurrently dependence on cocaine and opioids. Nicotine Tob Res 2002; 4: 223-8.
9. Story J., Stark M. J. Treating cigarette smoking in methadone maintenance clients. J Psychoact Drugs 1991; 23: 203-15.
10. Talka R., Salminen O., Tuominen R. K. Methadone is a non-competitive antagonist at the α4β2 and α3* nicotinic acetylcholine receptors and an agonist at the α7 nicotinic acetylcholine receptor. Basic Clin Pharmacol Toxicol 2014; 116: 321-8.
11. Clemmey P., Brooner R., Chutuape M. A., Kidorf M., Stitzer M. Smoking habits and attitudes in a methadone maintenance treatment population. Drug Alcohol Depend 1997; 4: 123-32.
12. Guydish J., Passalacqua E., Tajima B., Chan M., Chun J., Bostrom A. Smoking prevalence in addiction treatment: a review. Nicotine Tob Res 2011; 13: -401-11.
13. Nahvi S., Richter K., Li X., Modali L., Arnsten J. Cigarette smoking and interest in quitting in methadone maintenance patients. Addict Behav 2006; 31: 2127-34.
14. Richter K. P., Gibson C. A., Ahluwalia J. S., Schmelzle K. H. Tobacco use and quit attempts among methadone maintenance clients. Am J Public Health 2001; 91: 296-9.
15. Centers for Disease Control and Prevention. Current Cigarette Smoking Among Adults-United States, 2005-2012. MMWR Morb Mortal Wkly Rep 2014; 63: 29-34.
16. Hser Y. I., McCarthy W. J., Anglin M. D. Tobacco use as a distal predictor of mortality among long-term narcotic addicts. Prev Med 1994; 23: 61-9.
17. Hurt R. D., Offord K. P., Croghan I. T., Gomez-Dahl L., Kottke T. E., Morse R. M., Melton L. J. Mortality following inpatient addictions treatment: Role of tobacco use in a community-based cohort. JAMA 1996; 275: 1097-103.
18. Abbott P. J. Ongoing evaluation of patients' needs in an opioid treatment program. Prof Case Manag 2010; 15: 145-52.
19. Clark J. G., Stein M. D., McGarry K. A., Gogineni A. Interest in smoking cessation among injection drug users. Am J Addict 2001; 10: 159-66.
20. Frosch D. L., Shoptaw S., Jarvik M. E., Rawson R. A., Ling W. Interest in smoking cessation among methadone maintained outpatients. J Addict Dis 1998; 17: 9-19.
21. Olsen Y., Alford D. P., Horton N. J., Saitz R. Addressing smoking cessation in methadone programs. J Addict Dis 2005; 24: 33-48.
22. Sees K. L., Clark H. W. When to begin smoking cessation in substance abusers. J Subst Abuse Treat 1993; 10: 189-95.
23. Miller M.E., Sigmon S.C. Are pharmacotherapies ineffective in opioid-dependent smokers? Reflections on the scientific literature and future directions. Nicotine Tob Res 2015; 17: 955-9.
24. Nahvi S., Ning Y., Segal K. S., Richter K. P., Arnsten J. H. Varenicline efficacy and safety among methadone maintained smokers: a randomized placebo-controlled trial. Addiction 2014; 109: 1554-63.
25. Poling J, Rounsaville B, Gonsai K, Severino K, Sofuoglu M. The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: a pilot study. Am J Addict 2010;19: 401-8.
26. Reid M. S., Fallon B., Sonne S., Flammino F., Nunes E. V., Jiang H. et al. Smoking cessation treatment in community-based substance-abuse rehabilitation programs. J Subst Abuse Treat 2008; 35: 68-77.
27. Richter K. P., McCool R. M., Catley D., Hall M., Ahluwalia J. S. Dual pharmacotherapy and motivational interviewing for tobacco dependence among drug treatment facilities. J Addict Dis 2005; 24: 79-90.
28. Stein M. D., Weinstock M. C., Herman D. S., Anderson B. J., Anthony J. L., Niaura R. A smoking cessation intervention for the methadone-maintained. Addiction 2006; 101: 599-607.
29. Stein M. D., Caviness C. M., Kurth M. E., Audet D., Olson J., Anderson B. J. Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial. Drug Alcohol Depend 2013; 133: 486-93.
30. Mooney M. E., Poling J., Gonzalez G., Gonsai K., Kosten T., Sofuoglu M. Preliminary study of buprenorphine and bupropion for opioid dependent smokers. Am J Addict 2008; 17: 287-92. .
31. Schmitz J. M., Rhoades H., Grabowski J. Contingent reinforcement for reduced carbon monoxide levels in methadone maintenance patients. Addict Behav 1995; 20: 171-9.
32. Shoptaw S., Jarvik M. E., Ling W., Rawson R. A. Contingency management for tobacco smoking in methadone-maintained opiate addicts. Addict Behav 1996; 21: 409-12.
33. Shoptaw S., Rotheram-Fuller E., Yang X., Frosch D., Nahom D., Jarvik M. et al. Smoking cessation in methadone maintenance. Addiction 2002; 97: 1317-28.
34. Okoli C. T., Khara M., Procyshyn R. M., Johnson J. L., Barr A. M. Smoking cessation interventions among individuals in methadone maintenance: a brief review. J Subst Abuse Treat 2010; 38: 191-9.
35. Sigmon S. C., Patrick M. E. The use of financial incentives in promoting smoking cessation. Prev Med 2012; 55: S24-32.
36. Griffith J. D., Rowan-Szal G. A., Roark R. R., Simpson D. D. Contingency management in outpatient methadone treatment: a meta-analysis. Drug Alcohol Depend 2000; 58: 55-66.
37. Lussier J. P., Heil S. H., Mongeon J. A., Badger G. A., Higgins S.T. A meta-analysis of voucher-based reinforcement therapy for substance use disorders. Addiction 2006; 101: 192-203.
38. Roll J. M., Higgins S. T., Badger G. J. An experimental comparison of three different schedules of reinforcement of drug abstinence using cigarette smoking as an exemplar. J Appl Behav Anal 1996; 29: 495-504.
39. Roll J. M., Higgins S. T. A within-subject comparison of three different schedules of reinforcement of drug abstinence using cigarette smoking as an exemplar. Drug Alcohol Depend 2000; 58: 103-9.
40. Silverman K., Chutuape M. A., Bigelow G. E., Stitzer M. L. Voucher-based reinforcement of cocaine abstinence in treatment-resistant methadone patients: Effects of reinforcement magnitude. Psychopharmacology (Berl) 1999; 146: 128-38.
41. Frosch D. L., Nahom D., Shoptaw S. Optimizing smoking cessation outcomes among the methadone maintained. J Subst Abuse Treat 2002; 23: 425-30.
42. Gourlay S. G., Forbes A., Marriner T., Pethica D., McNeil J. J. Prospective study of factors predicting outcome of transdermal nicotine treatment in smoking cessation. BMJ 1994; 309: 842-6.
43. Higgins S. T., Heil S. H., Dumeer A. M., Thomas C. S., Solomon L. J., Bernstein I. M. Smoking status in the initial weeks of quitting as a predictor of smoking-cessation outcomes in pregnant women. Drug Alcohol Depend 2006; 85: 138-41.
44. Kenford S. L., Fiore M. C., Jorenby D. E., Smith S. S., Wetter D., Baker T. B. Predicting smoking cessation. Who will quit with and without the nicotine patch. JAMA 1994; 271: 589-94.
45. Yudkin P. L., Jones L., Lancaster T., Fowler G. H. Which smokers are helped to give up smoking using transdermal nicotine patches? Results from a randomized, double-blind, placebo-controlled trial. Br J Gen Pract 1996; 46: 145-8.
46. National Cancer Institute. Clearing the Air: Quit Smoking Today. Publication No. P133. Bethesda, MD: National Institutes of Health, US Department of Health and Human Services; 2003.
47. Dunn K. E., Sigmon S. C., Thomas C. S., Heil S. H., Higgins S. T. Voucher-based contingent reinforcement of smoking abstinence among methadone-maintained patients: a pilot study. J Appl Behav Anal 2008; 41: 527-38.
48. Dunn K. E., Sigmon S. C., Reimann E. F., Badger G. J., Heil S. H., Higgins S. T. A contingency-management intervention to promote initial smoking cessation among opioid-maintained patients. Exp Clin Psychopharmacol 2010; 18: 37-50.
49. McLellan A. T., Luborsky L., Cacciola J., Griffith J., Evans F., Barr H. L., et al. New data from the Addiction Severity Index, reliability and validity in three centers. J Nerv Ment Dis 1985; 173: 412-23.
50. Fagerström K. O., Schneider N. G. Measuring nicotine dependence: a review of the Fagerström Tolerance Questionnaire. J Behav Med 1989; 12: 159-82.
51. Heatherton T. F., Kozlowski L. T., Frecker R. C., Fagerström K. O. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991; 86: 1119-27.
52. Hughes J. R., Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 1986; 43: 289-94.
53. Shiffman S., Waters A., Hickcox M. The nicotine dependence syndrome scale: a multidimensional measure of nicotine dependence. Nicotine Tob Res 2004; 6: 327-48.
54. Tiffany S. T., Drobes D. J. The development and initial validation of a questionnaire on smoking urges. Br J Addict 1991; 86: 1467-76.
55. Selzer M. L. The Michigan Alcoholism Screening Test: the quest for a new diagnostic instrument. Am J Psychiatry 1971; 127: 1653-8.
56. Sobell L. C., Sobell M. B., Leo G. I., Cancilla A. Reliability of a timeline method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. Br J Addict 1988; 83: 393-402.
57. Beck A. T., Beck R. W. Screening depressed patients in family practice: a rapid technique. Postgrad Med 1972; 52: 81-5.
58. Beck A. T., Epstein N., Brown G., Steer R. A. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988; 56: 893-7.
59. Derogatis L. R. Brief Symptom Inventory. National Computer Systems, Inc.: Minneapolis, MN; 1993.
60. Fiore M. C., Bailey W. C., Cohen S. J. Treating Tobacco Use and Dependence: Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services, US Public Health Service; 2000.
61. Fiore M. C., Jaén C. R., Baker T. B., Bailey W. C., Benowitz N. L., Curry S. J. et al. Treating Tobacco Use and Dependence: 2008 Update. Rockville, MD: US Department of Health and Human Services, US Public Health Service; 2008.
62. Cox L. S., Tiffany S. T., Christen A. G. Evaluation of the Brief Questionnaire of Smoking Urges (QSU-B) in laboratory and clinical settings. Nicotine Tob Res 2001; 3: 7-16.
63. Altman D. G., Bland J. M. Treatment allocation by minimization. BMJ 2005; 330: 843.
64. Bigelow G. E., Stitzer M. L., Griffiths R. R., Liebson I. A. Contingency management approached to drug self-administration and drug abuse: efficacy and limitations. Addict Behav 1981; 6: 241-52.
65. Patrick M. E., Dunn K. E., Badger G. J., Heil S. H., Higgins S. T., Sigmon S. C. Spontaneous reductions in smoking during double-blind buprenorphine detoxification. Addict Behav 2014; 39: 1353-6.
66. Higgins S. T., Budney A. J., Hughes J. R., Bickel W. K., Lynn M., Mortensen A. Influence of cocaine use on cigarette smoking. JAMA 1994; 272: 1724.
67. Roll J. M., Higgins S. T., Tidey J. Cocaine use can increase cigarette smoking: evidence from laboratory and naturalistic settings. Exp Clin Psychopharmacol 1997; 5: 263-8.
68. Schmitz J. M., Grabowski J., Rhoades H. The effects of high and low doses of methadone on cigarette smoking. Drug Alcohol Depend 1994; 34: 237-42.
69. Kotz D., Fideler J., West R. Factors associated with the use of aids to cessation in English smokers. Addiction 2009; 104: 1403-10.
70. Shiffman S., Di Marino M. E., Sweeney C. T. Characteristics of selectors of nicotine replacement therapy. Tob Control 2005; 14: 346-55.
71. Kaper J., Wagena E. J., Willemsen M. C., van Schayck C. P. Reimbursement for smoking cessation treatment may double the abstinence rate: results of a randomized trial. Addiction 2005; 100: 1012-20.
72. Stitzer M., Bigelow G., Lawrence C., Cohen J., D'Lugoff B., Hawthorne J. Medication take-home as a reinforcer in a methadone maintenance program. Addict Behav 1977; 2: 9-14.
73. Higgins S. T. Comments on contingency management and conditional cash transfers. Health Econ 2010; 19: 1255-8.
74. ® at http://www.webcitation.org/6eHujE0Hv) (accessed 4 December 2016).
75. ® at http://www.webcitation.org/6eHuUZNMW) (accessed 4 December 2016).
76. Ashare R.L., Wileyto E.P., Perkins K.A., Schnoll R.A. The first 7 days of a quit attempt predicts relapse: validation of a measure for screening medications for nicotine dependence. J Addict Med 2013; 7: 249-54.